Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-binding growth factor isolated from human prostatic extracts.

J H Mydlo1, M A Bulbul, V M Richon

  • 1Urologic Oncology Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

The Prostate
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.

International journal of urology : official journal of the Japanese Urological Association·2013
Same author

Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.

Oncogene·2012
Same author

Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.

Leukemia·2012
Same author

Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.

Oncogene·2011
Same author

Purification of Growth Factor mRNA in Renal Tissues:bFGF-2, FGF-2, TGFα, and EGFR.

Methods in molecular medicine·2011
Same author

Angiogenesis assays.

Methods in molecular medicine·2011
Same journal

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.

The Prostate·2026
Same journal

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia.

The Prostate·2026
Same journal

Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United States.

The Prostate·2026
Same journal

Holmium Laser Enucleation of the Prostate (HoLEP) With Proactive Preservation of One Lateral Lobe: A Technique for Benign Prostatic Hyperplasia to Preserve Sexual Function.

The Prostate·2026
Same journal

Clinical Variable-Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation.

The Prostate·2026
Same journal

Association Between Intraoperative Prostate Bed Blood Flow and Postoperative Lower Urinary Tract Symptoms After Robot-Assisted Radical Prostatectomy.

The Prostate·2026
See all related articles

Prostatic growth factor (PrGF) isolated from benign prostatic hyperplasia and carcinoma tissues exhibits mitogenic and angiogenic properties. This factor shares homology with basic fibroblast growth factors (bFGF).

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Benign prostatic hyperplasia (BPH) and prostatic carcinoma involve complex cellular processes.
  • Understanding the molecular factors influencing prostatic tissue growth is crucial for therapeutic development.

Purpose of the Study:

  • To isolate and characterize mitogenic factors from human prostatic tissues.
  • To investigate the biological activities and identify the nature of these prostatic growth factors.

Main Methods:

  • Heparin-Sepharose chromatography for fractionating prostatic tissue extracts.
  • Tritiated-thymidine incorporation assays to assess mitogenic activity on fibroblasts and osteoblasts.
  • SDS-PAGE and Western blot analysis for protein identification and characterization.

Related Experiment Videos

  • Chick embryo chorioallantoic membrane (CAM) assay for angiogenic properties.

    • Main Results:

    • Two peaks of mitogenic activity were identified in prostatic extracts.
    • A heparin-binding fraction, eluting at 1.3-1.6 M NaCl, contained the majority of mitogenic activity.
    • The purified protein (17,500 daltons) demonstrated angiogenic properties.
    • Western blot analysis indicated homology with basic fibroblast growth factor (bFGF).

    Conclusions:

    • Prostatic growth factor (PrGF) possesses significant mitogenic and angiogenic potential.
    • PrGF appears to be a heparin-binding protein homologous to basic fibroblast growth factor.
    • Further research into PrGF could offer insights into BPH and prostatic cancer pathogenesis.